Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 431-870-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Bacterial gene mutation study
A bacterial gene mutation study was carried out for BMS 217947-01. The bacterial strains were exposed to concentrations of 50 to 5000 μg substance per plate, both with and without metabolic activation.
A dose-related, reproducible and statistically significant increase in revertant colony frequency was observed in tester strains TA 100 and TA 1535 both with and without metabolic reaction. The first indication of a mutagenic response was observed at 150µg/plate in tester strain TA 1535 without metabolic reaction. No mutagenic response was observed in Salmonella typhimurium strains TA98 and TA1537 at the any of the doses used.
Mouse lymphoma assay
A mouse lymphoma assay test in L5178Y cells was carried out for BMS 217947-01, according to Directive 88/302/EEC, Part B, OECD Guideline No.476 and US EPA (1998) Health Effects Test Guidelines OPPTS 870.5300. In-vitro mammalian cell gene mutation tets EPA 712-C-98-221. Three tests were carried out with different exposure concentrations and exposure periods (3h and 24h), both with and without metabolic activation.
Statistically significant increases in mutant frequency outside the historical control range with a Day 0 survival of more than 10%, were observed in Test 1 at 135µg/ml and in Test 3 at 25µg/ml in the absence of S-9 mix. As these increases were outside the historical control range with a Day 0 survival of more than 10% they were considered to be of biological significance.
Statistically significant increases in mutant frequency were observed in all of the tests at 200µg/ml in the presence of S-9 mix. These increases were outside the historical control range with a Day 0 survival of more than 10%. Therefore, they were considered to be of biological significance.
In vivo micronucleus
An in vivo micronucleus assay was carried out on BMS 217947-01 according to EEC Directive 92/69/EEC, Method B12 and OECD Guidelines for testing of Chemicals No. 474 "Micronucleus Test". The test was carried out on albino, CD-1 (ICR)BR mice. The material was administered orally to groups of 7 rats at doses of 250, 500 and 1000 mg/kg, dispersed in arachis oil.
There was no evidence of a significant increase in the incidence of micronucleated polychromatic erythrocytes in animals dosed with the test material when compared to the concurrent vehicle control groups. No statistically significant decreases in the PCE/NCE ratio were observed in the 24 or 48-hour test material dose groups when compared to their concurrent control groups.
In vivo Comet Assay
This study was conducted to determine the potential genotoxicity of BMS-217947-01, when given to rats for a 2-day period by evaluating DNA damage in the duodenum and liver using the alkaline comet assay. BMS-217947-01 was administered by oral gavage at doses of 0(vehicle), 100, 500, or 1000mg/kg/day to groups of 6 male rats at dose volumes of 10, 1, 5, and 10mL/kg, respectively. The vehicle/carrier consisted of peanut oil. The positive control rats were dosed with ethyl methanesulfonate (EMS) at a dose of 200 mg/kg via intraperitoneal injection3 to 4 hours prior to necropsy. BMS-217947-01 induced a statistically significant dose-related increase in duodenum mean %TI at 1000mg/kg/day, and statistically significant dose-related increases in mean and median liver %TI at 500 and 1000mg/kg/day. Anatomically, there were dose-related randomly distributed minimal to mildly increased hepatocytic mitotic figures at ≥ 500 mg/kg/day, which suggests increased DNA repair. In conclusion, BMS-217947-01was genotoxic in liver at 500mg/kg/day and in duodenum at 500 and 1000 mg/kg/day.
Conclusion
Under a weight of evidence assessemnt of the in-vitro and in-vivo studies, the material was considered mutagenic and genotoxic in bacterial and mammalian cell systems in vitro in the absence and presence of hepatic S9 fractions.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29 October 1998 - 13 November 1998
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: done under OECD method and GLP
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Principles of method if other than guideline:
- This study was conducted according to Safepharm Standard Method 700.04. The method conforms to the guidelines for bacterial mutagenicity testing published by the major Japanese Regulatory Authorities including MITI, MHW, MOL and MAFF. It also meets the requirements of the OECD, EC and USA, EPA (TSCA) guidelines
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Metabolic activation:
- with and without
- Metabolic activation system:
- Liver homogenate derived from Aroclor 1254 induced rats (S-9 mix),
- Test concentrations with justification for top dose:
- Concentration range in the main test (with metabolic activation): 50 ... 5000 µg/plate
Concentration range in the main test (without metabolic activation): 50 ... 5000 µg/plate - Vehicle / solvent:
- Solvent: Dimethyl sulphoxide
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- not specified
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Remarks:
- (> 5000 µg/plate)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- not specified
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Remarks:
- (> 5000 µg/plate)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1535 pSK1002
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Remarks:
- (> 5000 µg/plate)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Remarks:
- (> 5000 µg/plate)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Remarks:
- (> 5000 µg/plate)
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Observations:
A dose-related, reproducible and statistically significant increase in revertant colony frequency was observed in tester strains TA 100 and TA 1535 both with and without metabolic reaction. The first indication of a mutagenic response was observed at 150µg/plate in tester strain TA 1535 without metabolic reaction. No mutagenic response was observed in Salmonella typhimurium strains TA98 and TA1537 at the any of the doses used. - Remarks on result:
- other: other: preliminary test
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
positive with metabolic activation
positive without metabolic activation
The test material was considered to be mutagenic under the conditions of the test. - Executive summary:
A bacterial gene mutation study was carried out for BMS 217947-01. The bacterial strains were exposed to concentrations of 50 to 5000 μg substance per plate, both with and without metabolic activation.
A dose-related, reproducible and statistically significant increase in revertant colony frequency was observed in tester strains TA 100 and TA 1535 both with and without metabolic reaction. The first indication of a mutagenic response was observed at 150µg/plate in tester strain TA 1535 without metabolic reaction. No mutagenic response was observed in Salmonella typhimurium strains TA98 and TA1537 at the any of the doses used.
Therefore, under the conditions of the test, the material was considered to be mutagenic.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 July 1999 - 4th Oct 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: done under OECD method and GLP
- Qualifier:
- according to guideline
- Guideline:
- other: 1.Directive 88/302/EEC, Part B;OECD Guideline No.476 2.US EPA (1998) Health Effects Test Guidelines OPPTS 870.5300. In-vitro mammalian cell gene mutation tets EPA 712-C-98-221
- GLP compliance:
- yes
- Type of assay:
- mammalian cell gene mutation assay
- Species / strain / cell type:
- mammalian cell line, other: Mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Metabolic activation system:
- Aroclor-induced rat liver S-9
- Test concentrations with justification for top dose:
- Concentration range in the main test (with metabolic activation): 50 ... 250 µg/ml
Concentration range in the main test (with metabolic activation): 30 ... 200 µg/ml
Concentration range in the main test (with metabolic activation): 30 ... 250 µg/ml
Concentration range in the main test (without metabolic activation): 25 ... 135 µg/ml
Concentration range in the main test (without metabolic activation): 1 ... 25 µg/ml
Concentration range in the main test (without metabolic activation): 10 ... 30 µg/ml - Vehicle / solvent:
- Dimethylsulphoxide (DMSO)
- Details on test system and experimental conditions:
- Exposure period (with metabolic activation): 3 hours
Exposure period (without metabolic activation): 3 hours
Expression time:
48 hours
Selection time:
10-14 days for mutant frequency. Selective agent TFT
Fixation time:
Exposure period without metabolic activation:
First test:3 hours
Second test: 24 hours - Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with
- Genotoxicity:
- not determined
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- ( 125 µg/ml)
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- without
- Genotoxicity:
- not determined
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- ( 15 µg/ml)
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- ( 150 µg/ml)
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- ( 10 µg/ml)
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Observations:
Statistically significant increases in mutant frequency
outside the historical control range with a Day 0 survival
of more than 10%, were observed in Test 1 at 135µg/ml and in
Test 3 at 25µg/ml in the absence of S-9 mix. As these
increases were outside the historical control range with a
Day 0 survival of more than 10% they were considered to be
of biological significance.
Statistically significant increases in mutant frequency were
observed in all of the tests at 200µg/ml in the presence of
S-9 mix. These increases were outside the historical control
range with a Day 0 survival of more than 10%. Therefore,
they were considered to be of biological significance. - Remarks on result:
- other: other: preliminary test
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
positive with metabolic activation
positive without metabolic activation
it was concluded that BMS 247947-01 did demonstrate mutagenic potential in this in vitro gene mutation assay - Executive summary:
A mouse lymphoma assay test in L5178Y cells was carried out for BMS 217947-01, according to Directive 88/302/EEC, Part B, OECD Guideline No.476 and US EPA (1998) Health Effects Test Guidelines OPPTS 870.5300. In-vitro mammalian cell gene mutation tets EPA 712-C-98-221. Three tests were carried out with different exposure concentrations and exposure periods (3h and 24h), both with and without metabolic activation.
Statistically significant increases in mutant frequency outside the historical control range with a Day 0 survival of more than 10%, were observed in Test 1 at 135µg/ml and in Test 3 at 25µg/ml in the absence of S-9 mix. As these increases were outside the historical control range with a Day 0 survival of more than 10% they were considered to be of biological significance.
Statistically significant increases in mutant frequency were observed in all of the tests at 200µg/ml in the presence of S-9 mix. These increases were outside the historical control range with a Day 0 survival of more than 10%. Therefore, they were considered to be of biological significance.
Therefore, under the conditions of the test, the material was considered to be mutagenic.
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Genetic toxicity in vivo
Description of key information
In Vivo Micronucleus Assay
An in vivo micronucleus assay was carried out on BMS 217947-01 according to EEC Directive 92/69/EEC, Method B12 and OECD Guidelines for testing of Chemicals No. 474 "Micronucleus Test". The test was carried out on albino, CD-1 (ICR)BR mice. The material was administered orally to groups of 7 rats at doses of 250, 500 and 1000 mg/kg, dispersed in arachis oil.
In the range finding toxicity study, the toxicity observed at 2000 mg/kg was considered to be excessive, therefore, the maximum tolerated dose (MTD) of the test material, 1000 mg/kg, was selected for use in the main study, with 500 and 250 mg/kg as the lower dose levels. In animals dosed with the test material via the oral route one premature death occurred at 2000 mg/kg, and clinical signs were observed at and above 1000 mg/kg as follows: hunched posture, lethargy, ataxia, decreased respiratory rate, laboured respiration, tonic convulsions, increased salivation, splayed gait, pilo-erection, tiptoe gait, emaciation, ptosis and distended abdomen. These clinical signs indicate that systemic absorption had taken place.
Observations:
There was no evidence of a significant increase in the incidence of micronucleated polychromatic erythrocytes in animals dosed with the test material when compared to the concurrent vehicle control groups. No statistically significant decreases in the PCE/NCE ratio were observed in the 24 or 48-hour test material dose groups when compared to their concurrent control groups. However, the presence of clinical signs indicated that systemic absorption had occurred.
The test material, BMS 217947-01, tested negative in the test and was thus considered to be non-genotoxic under the conditions of the test.
A InVivo Mammalian Alkaline Comet Assay was conducted in accordance with OECD (2016), Test No. 489
A Comet assay was conducted determine the potential genotoxicity of BMS-217947-01, when given to rats for a 2-day period by evaluating DNA damage in the duodenum and liver using the alkaline comet assay. BMS-217947-01 was administered by oral gavage at doses of 0 (vehicle), 100, 500, or 1000mg/kg/day to groups of 6 male rats at dose volumes of 10, 1, 5, and 10mL/kg, respectively. The vehicle/carrier consisted of peanut oil. The positive control rats were dosed with ethyl methanesulfonate(EMS) at a dose of 200 mg/kg via intraperitoneal injection3 to 4 hours prior to necropsy.
BMS-217947-01 was well tolerated with no recordable clinical observations or mortality throughout the dosing period.
BMS-217947-01 induced a statistically significant dose-related increase in duodenum mean %TI at 1000mg/kg/day, and statistically significant dose-related increases in mean and median liver %TI at 500 and 1000mg/kg/day.
In conclusion, BMS-217947-01was genotoxic in liver at 500mg/kg/day and in duodenum at 500 and 1000 mg/kg/day
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 Nov 1998 - 11 March 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: done under OECD method and GLP
- Qualifier:
- according to guideline
- Guideline:
- other: EEC Directive 92/69/EEC, Method B12, OECD Guidelines for testing of Chemicals No. 474 "Micronucleus Test".
- GLP compliance:
- yes
- Type of assay:
- micronucleus assay
- Species:
- mouse
- Strain:
- CD-1
- Remarks:
- albino, (ICR)BR
- Route of administration:
- oral: unspecified
- Vehicle:
- Arachis oil
- No. of animals per sex per dose:
- Male: 1000 mg/kg; No. of animals: 7; Sacrifice time: 48 hours
Male: 1000 mg/kg; No. of animals: 7; Sacrifice time: 24 hours
Male: 500 mg/kg; No. of animals: 7; Sacrifice time: 24 hours
Male: 250 mg/kg; No. of animals: 7; Sacrifice time: 24 hours - Additional information on results:
- Doses producing toxicity:
In the range finding toxicity study, the toxicity observed at 2000 mg/kg was considered to be excessive, therefore, the maximum tolerated dose (MTD) of the test material, 1000 mg/kg, was selected for use in the main study, with 500 and 250 mg/kg as the lower dose levels. In animals dosed with the test material via the oral route one premature death occurred at 2000 mg/kg, and clinical signs were observed at and above 1000 mg/kg as follows: hunched posture, lethargy, ataxia, decreased respiratory rate, laboured respiration, tonic convulsions, increased salivation, splayed gait, pilo-erection, tiptoe gait, emaciation, ptosis and distended abdomen. These clinical signs indicate that systemic absorption had taken place.
Observations:
There was no evidence of a significant increase in the incidence of micronucleated polychromatic erythrocytes in animals dosed with the test material when compared to the concurrent vehicle control groups. No statistically significant decreases in the PCE/NCE ratio were observed in the 24 or 48-hour test material dose groups when compared to their concurrent control groups. However, the presence of clinical signs indicated that systemic absorption had occurred. - Conclusions:
- Interpretation of results (migrated information): negative
The test material, BMS 217947-01, was considered to be non-genotoxic under the conditions of the test. - Executive summary:
An in vivo micronucleus assay was carried out on BMS 217947-01 according to EEC Directive 92/69/EEC, Method B12 and OECD Guidelines for testing of Chemicals No. 474 "Micronucleus Test". The test was carried out on albino, CD-1 (ICR)BR mice. The material was administered orally to groups of 7 rats at doses of 250, 500 and 1000 mg/kg, dispersed in arachis oil.
In the range finding toxicity study, the toxicity observed at 2000 mg/kg was considered to be excessive, therefore, the maximum tolerated dose (MTD) of the test material, 1000 mg/kg, was selected for use in the main study, with 500 and 250 mg/kg as the lower dose levels. In animals dosed with the test material via the oral route one premature death occurred at 2000 mg/kg, and clinical signs were observed at and above 1000 mg/kg as follows: hunched posture, lethargy, ataxia, decreased respiratory rate, laboured respiration, tonic convulsions, increased salivation, splayed gait, pilo-erection, tiptoe gait, emaciation, ptosis and distended abdomen. These clinical signs indicate that systemic absorption had taken place.
Observations:
There was no evidence of a significant increase in the incidence of micronucleated polychromatic erythrocytes in animals dosed with the test material when compared to the concurrent vehicle control groups. No statistically significant decreases in the PCE/NCE ratio were observed in the 24 or 48-hour test material dose groups when compared to their concurrent control groups. However, the presence of clinical signs indicated that systemic absorption had occurred.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Additional information
Justification for classification or non-classification
Two in vitro mutagenicity tests (bacterial mutation and mouse lymphoma assay) returned positive results on potential for mutagenicity of BMS 217947-01. One in vivo test on mice (micronucleus assay), showed negative results and a 2 day oral COMET assay in rats resulted in a positive result. Based on a weight of evidence approach the material has the potential to be genotoxic.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.